Valuation: AbbVie Inc.

Market Cap 462B 15,529B 407B 386B 348B 656B 44,323B 665B 4,614B 1,776B 22,659B 1,736B 1,698B 72,645B P/E 2026 *
33.1x
P/E 2027 * 24.7x
Enterprise Value 524B 17,598B 461B 437B 395B 744B 50,228B 753B 5,229B 2,012B 25,678B 1,967B 1,924B 82,324B EV / Sales 2026 *
7.75x
EV / Sales 2027 * 7.01x
Free-Float
95.71%
Yield 2026 *
2.65%
Yield 2027 * 2.76%
1 day-1.12%
1 week-0.56%
1 month+4.14%
3 months+3.53%
6 months+24.82%
Current year+20.55%
1 week 8.75
Extreme 8.75
9
1 month 8.15
Extreme 8.15
9
Current year 6.25
Extreme 6.25
9
1 year 6.25
Extreme 6.25
9
3 years 6.25
Extreme 6.25
9
5 years 6.25
Extreme 6.25
9
10 years 6.25
Extreme 6.25
9
Manager TitleAgeSince
Chief Executive Officer 55 2024-06-30
Director of Finance/CFO 59 2022-06-22
Chief Tech/Sci/R&D Officer - 2024-02-29
Director TitleAgeSince
Director/Board Member 65 2012-12-31
Director/Board Member 74 2012-12-31
Director/Board Member 69 2012-12-31
Change 5-day change 1-year change 3-year change Capi.($)
-1.12%-0.56% - - 462B
-0.72%+0.53%+51.65%+115.42% 1,031B
-0.64%-1.65%+42.78%+69.98% 638B
-0.49%-1.32%+12.98%+75.49% 462B
-0.64%-1.87%+73.13%+41.15% 359B
+0.60%-3.36%+24.41%+41.58% 335B
-0.93%+0.05%+14.42%+27.47% 273B
-0.80%-1.97%-2.25%+11.01% 253B
-0.21%+3.80%+49.37%+56.84% 228B
-0.16%-1.53%+34.28%+98.89% 185B
Average -0.55%-0.36%+33.42%+59.76% 418.21B
Weighted average by Cap. -0.64%-0.35%+37.70%+71.41%

Financials

2026 *2027 *
Net sales 67.6B 2,271B 59.53B 56.4B 50.92B 95.97B 6,482B 97.21B 675B 260B 3,314B 254B 248B 10,623B 73.5B 2,469B 64.72B 61.32B 55.36B 104B 7,047B 106B 734B 282B 3,603B 276B 270B 11,550B
Net income 14.07B 473B 12.39B 11.74B 10.6B 19.97B 1,349B 20.23B 140B 54.04B 690B 52.82B 51.67B 2,211B 19.05B 640B 16.77B 15.89B 14.35B 27.04B 1,826B 27.39B 190B 73.17B 934B 71.52B 69.96B 2,993B
Net Debt 61.59B 2,069B 54.24B 51.39B 46.39B 87.44B 5,906B 88.57B 615B 237B 3,019B 231B 226B 9,679B 53.09B 1,784B 46.75B 44.3B 39.99B 75.37B 5,091B 76.35B 530B 204B 2,602B 199B 195B 8,343B
Logo AbbVie Inc.
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (76.2%), Germany (2.8%), Japan (2.1%), Canada (2%), China (1.6%), France (1.3%), the United Kingdom (1%), Spain (1%), Italy (0.9%), Brazil (0.8%), Australia (0.8%), and Other (9.5%).
Employees
57,000
Date Price Change Volume
26-09-30 THB 8.800 -1.12% 41,191
26-09-29 THB 8.900 -0.56% 3,685
26-09-28 THB 8.950 +1.13% 2,308
26-09-25 THB 8.850 +0.57% 14,085
26-09-24 THB 8.800 -0.56% 29,190
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
30
Last Close Price
261.59USD
Average target price
278.86USD
Spread / Average Target
+6.60%

Quarterly revenue - Rate of surprise